Waiting for breast biopsy results is often harder than the biopsy itself. The good news is that most breast biopsies do not show cancer. The less obvious news is that a pathology report can say more than "benign" or "cancer", and that a benign result only counts once it has been checked against the original images. This article explains how long breast biopsy results usually take, the three kinds of result you can get, what the main terms on a pathology report mean, and what happens next in each case.
According to the American Cancer Society, it typically takes at least a few days to get the results of a breast biopsy. The tissue has to be fixed, processed, cut into very thin slices, stained and examined under the microscope by a pathologist, and each of those steps takes time.
Results can take longer when the pathologist needs extra tests. Special stains are sometimes used to tell a benign condition from an early cancer, and when cancer is found, the tumor is usually also tested for hormone receptors and HER2. Those extra tests can add several days. A longer wait therefore does not in itself mean bad news.
Ask at the biopsy appointment how and when you will be told. Some centers call, some use a patient portal, and many prefer to give the result in person, whatever it is. Knowing the plan in advance takes a surprising amount of stress out of the wait.
A breast biopsy result falls into one of three broad groups. Many European and UK centers also use a B-code from B1 to B5 on the report, which maps onto the same groups.
| Result | Common examples on the report | UK/EU code | Usual next step |
|---|---|---|---|
| Benign | Fibroadenoma, fibrocystic change, cyst, fat necrosis | B2 | Concordance check, then routine follow up |
| High risk or uncertain | Atypical ductal hyperplasia, lobular neoplasia, papilloma, radial scar | B3 | Removal of the area or close imaging follow up |
| Malignant | Ductal carcinoma in situ (DCIS), invasive ductal or lobular carcinoma | B5 | Treatment planning, usually including surgery |
B1 means the sample contained only normal tissue, which can mean the needle missed the target, and B4 means cells are suspicious but not conclusive. Both usually lead to a repeat biopsy. The American Cancer Society's guide to breast pathology reports explains many of the individual terms in more detail.
A benign result is the most common outcome, and for most people it is the end of the story. There is one step in between that is rarely explained: the radiologist compares the pathology result with what was seen on the mammogram, ultrasound or MRI. This is called radiologic pathologic concordance.
If the images showed a smooth, oval mass and the pathology says fibroadenoma, the two fit together and the result is concordant. If the images showed an irregular, spiculated mass and the pathology says normal breast tissue, they do not fit. That result is discordant, and it means the needle may have sampled tissue next to the lesion rather than the lesion itself. A discordant benign result is not accepted as benign. It is followed by a repeat biopsy or a surgical excision.
This is also one reason a marker is placed at the end of most breast biopsies. A follow up image showing the marker in the right spot is part of how the team confirms that the sample came from the target. Why that marker is used is covered in Clip Marker in Breast Cancer.
Some results are not cancer but are not entirely reassuring either. These are often called high risk lesions or lesions of uncertain malignant potential. The most discussed is atypical ductal hyperplasia (ADH), where cells look abnormal but do not meet the criteria for cancer.
The concern with these lesions is that a needle only takes a small sample, and a cancer may be sitting right next to the area that was sampled. When the whole area is later removed, a proportion turns out to contain cancer, which is called an upgrade. In a meta-analysis of 6,458 lesions, Schiaffino and colleagues found a pooled upgrade rate of 29 percent when needle-diagnosed ADH was surgically excised (doi: 10.1148/radiol.2019190748). Their conclusion was that ADH found on a needle biopsy should be removed.
For other high risk lesions, such as a small papilloma without atypia or a radial scar, practice varies more. Some centers remove them with a larger vacuum assisted needle instead of an operation, others recommend surgery, and some offer close imaging follow up. When surgery is chosen and the area cannot be felt, it is localized in exactly the same way as a small cancer.
A malignant result will name the type of cancer, usually DCIS, which is still confined to the milk ducts, or an invasive cancer such as invasive ductal or invasive lobular carcinoma. The report will usually also give the grade, which describes how abnormal the cells look, and the results of hormone receptor testing and HER2 testing. Those three pieces of information drive most treatment decisions.
Your case will then typically be discussed by a multidisciplinary team of surgeons, radiologists, pathologists and oncologists. For most early breast cancers, surgery is part of the plan, either a lumpectomy or a mastectomy, as explained in Lumpectomy vs Mastectomy. Specific types are covered in DCIS Surgery and Localization and Invasive Lobular Carcinoma and Localization. If the cancer cannot be felt, which is common for cancers found on screening, the operation needs a way to guide the surgeon to it, as described in Surgery for Non-Palpable Breast Cancer.
Usually at least a few days. Results can take longer when extra stains or receptor tests are needed, which does not in itself mean the result is cancer.
Not necessarily. Some centers only call when the result is ready to be discussed, whatever it is. If you have not heard anything after the time you were given, call the center rather than assume either way.
A needle biopsy is very reliable, but it is a sample. That is why the result is checked against the images. If the pathology and the images do not match, the result is treated as discordant and the area is sampled again or removed.
Atypical means the cells look abnormal under the microscope but do not meet the definition of cancer. Atypical ductal hyperplasia is usually removed, because when the whole area is examined, cancer is found in a meaningful share of cases.
If the result is benign, the small marker is usually left in place permanently. It is made of materials designed to stay in the body, and it helps radiologists recognize the biopsied area on future mammograms. If the result is cancer, the marker is removed together with the lesion during surgery.
No. Bruising and a small firm swelling are common after a breast biopsy and are not related to the result. What is normal and when to call is explained in Hematoma After Breast Biopsy.
When a biopsy result leads to surgery, for cancer or for a high risk lesion, the surgeon has to remove a target that often cannot be felt. Sirius Medical developed the Pintuition® system for that step. The Pintuition Marker® is a non radioactive, permanent magnetic marker that is cleared for long-term placement in soft tissue, so it can be placed well before the day of surgery instead of with a wire on the morning of the operation. During surgery, GPSDetect™ technology gives real-time distance and direction to the marker, and TargetLOC™ confirms when the probe is aligned directly above it. The signal stays accurate in blood, fluid and hematoma and is not affected by electrocautery.
In the first 200 cases at a French cancer center, published by Ceccato and colleagues in Scientific Reports (doi: 10.1038/s41598-025-88430-5), every targeted lesion was excised with a re-excision rate of 7.6 percent. A Stanford comparison with an alternative wireless technique, reported by Chinn and colleagues in Annals of Surgical Oncology (doi: 10.1245/s10434-025-18354-x), found a median operating time of 37 minutes versus 50 minutes. Elisabeth TweeSteden Hospital in the Netherlands has performed more than a thousand Pintuition® guided procedures.
Learn how Pintuition® can support precision, workflow efficiency and reliable excision in breast cancer surgery. Request demo or explore the clinical overview for more information.
Disclaimer
This article is intended for informational purposes only and should not be considered medical advice. Clinical decisions should always be made by qualified healthcare professionals based on individual patient needs and current guidelines.